


Half-year financial report 2016

Stable operational development

- Revenue with EUR 438.7 million slightly below previous year's level despite market weakness
 - Improved EBITDA margin (12.0%) and EBIT margin (8.3%)
- Strong performance of Industrial Sector largely compensated weaker development of Medical Sector
 - Enhanced global presence and good capacity utilisation
- Persistently challenging market environment expected for second half of 2016



Key performance figures

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	438.7	-2.7%	450.8	219.2	-6.1%	233.4	914.7
EBITDA	52.8	+4.8%	50.3	26.1	-8.6%	28.5	96.2
EBITDA margin	12.0%	+0.8 PP	11.2%	11.9%	-0.3 PP	12.2%	10.5%
EBIT	36.2	±0.0%	36.2	17.6	-16.2%	21.0	66.7
EBIT margin	8.3%	+0.3 PP	8.0%	8.0%	-1.0 PP	9.0%	7.3%
Earnings after tax	17.9	-29.3%	25.3	7.7	-39.2%	12.7	46.4
Earnings per share (EPS) ²⁾ , in EUR	0.87	-29.3%	1.23	0.38	-39.2%	0.62	2.26
Gross cash flow	36.2	10.5%	32.7	18.4	+17.2%	15.7	55.7
Return on equity ³⁾	10.0%	-4.0 PP	14.0%	8.7%	-5.4 PP	14.1%	12.8%

Balance sheet key figures

in EUR million	30.6.2016	Change	30.6.2015	31.3.2016	Change	31.3.2015	31.12.2015
Balance sheet total	973.1	+4.8%	928.1	960.3	+7.5%	892.9	937.8
Equity ²⁾	356.9	-1.7%	363.0	378.8	-23.2%	493.2	363.3
Equity ratio	36.7%	-2.4 PP	39.1%	39.4%	-15.8 PP	55.2%	38.7%
Investments in tangible and intangible assets	25.0	-22.5%	32.3	16.1	+11.1%	14.5	71.8
Employees (at balance sheet date)	7,136	-2.4%	7,311	6,965	+1.1%	6,889	7,053

Sector and segment key figures

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Industrial Sector = Semperflex + Sempertrans + Semperform							
Revenue	269.0	+3.7%	259.3	135.3	+1.6%	133.2	521.0
EBITDA	52.3	+2.3%	51.1	27.2	-6.3%	29.1	93.6
EBIT	42.7	-1.7%	43.4	22.4	-10.3%	25.0	77.2
Semperflex							
Revenue	106.3	-1.5%	107.9	53.6	+2.0%	52.5	203.4
EBITDA	27.2	+1.2%	26.9	13.9	+4.9%	13.3	46.1
EBIT	22.9	+0.1%	22.9	11.8	+4.6%	11.3	38.2
Sempertrans							
Revenue	81.6	+4.7%	77.9	38.9	-0.2%	39.0	164.9
EBITDA	11.4	+9.8%	10.4	5.7	-0.7%	5.7	23.2
EBIT	9.5	+8.1%	8.8	4.7	-3.4%	4.9	19.9
Semperform							
Revenue	81.1	+10.2%	73.5	42.8	+2.7%	41.7	152.8
EBITDA	13.6	-1.2%	13.8	7.7	-24.0%	10.1	24.3
EBIT	10.2	-12.5%	11.7	5.9	-33.0%	8.8	19.1
Medical Sector = Sempermed							
Revenue	169.7	-11.4%	191.5	83.8	-16.3%	100.1	393.7
EBITDA	7.9	-31.7%	11.6	1.8	-72.9%	6.8	29.4
EBIT	1.2	-78.1%	5.5	-1.7	-	3.6	17.2

Note: Rounding differences in the totalling of rounded amounts and percentages may arise from the use of automatic data processing.

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

²⁾ Attributable to the shareholders of Semperit AG Holding.

³⁾ Based on a full-year projection.

Economic environment and development in raw materials markets

The global economic environment remained challenging in the first half of 2016. In July 2016, the International Monetary Fund (IMF) corrected its forecast for the current year slightly downwards and forecasts a global economic growth of 3.1% for 2016. The IMF thus responded to the subdued development in the industrialised countries as well as to the increasing headwind and persistent geopolitical tensions in the emerging countries.

In the first two months of 2016, prices for natural rubber and natural latex as well as synthetic latex and synthetic rubber moved sideways or slightly declined compared to the end of 2015. Since the beginning of March 2016, almost all raw materials recorded a partly significant price increase, which compensated for a very significant part the tendencies at the beginning of the year. Depending on the raw material, average prices of the first half 2016 were more or less at the same level of the first half of 2015, however above the average prices of the second half of 2015.

Revenue and earnings of Semperit Group

First half of 2016

Revenue of the Semperit Group decreased from EUR 450.8 million in the first half of 2015 to EUR 438.7 million in the first half of 2016, a decrease of 2.7%. The decrease in revenue in the first half of 2016 was due to lower revenues of the Medical Sector that was influenced by high price pressure and the focus on high-margin customer relationships. The revenue split slightly shifted in favour of the Industrial Sector. In the first half of 2016 the Industrial Sector accounted for 61% (39% Medical Sector), after 58% in the first half of 2015 (42% Medical Sector).

As an internationally operating group, Semperit is subject to various foreign exchange effects within the scope of its business activities. For the purpose of a more effective internal management as well as a more transparent presentation in the external financial reports of Semperit Group and its segments, foreign exchange gains or losses in the consolidated income statement are not shown as part of the operating result in "Other operating income" or "Other operating expenses" anymore since 1 January 2016, but in financial income / financial expenses and are therefore part of the financial results. In order to guarantee comparability with the quarters of the previous year and the previous year following the change of method pursuant to IAS 8, all comparable figures for 2015 are presented according to the same new reporting method in this report.

Other operating income dropped from EUR 7.0 million to EUR 5.7 million in the first half of 2016. In the first half of 2016, they had been positively influenced by the claim for reimbursement from the arbitration proceedings ICC 1 amounting to EUR 2.5 million. In the first half of 2015, earnings from the acquisition of Leeser, Germany, amounting to EUR 3.1 million, were included.

In the first half of 2016, inventories decreased by EUR 3.8 million (increase in inventories by EUR 3.0 million in the first half of 2015).

Due to active raw material management and the decrease of inventories, cost of materials fell from EUR 273.3 million to EUR 247.0 million compared to the first half of 2015, a decrease of 9.6%.

Personnel expenses rose by 5.2% to EUR 87.9 million, due to increases in salaries and wages.

Other operating expenses fell by 8.9% due to lower legal and consulting expenses to EUR 57.9 million compared with the first half of 2015.

In the first half of 2016, EBITDA (earnings before interest, tax, depreciation and amortisation) totalled EUR 52.8 million (a plus of 4.8%). The EBITDA margin increased from 11.2% to 12.0%. Depreciation increased in accordance with capacity extensions to EUR 16.5 million.

At EUR 36.2 million, EBIT remained almost exactly on the same level as in the first half of 2015. The EBIT margin slightly increased to 8.3%.

Key figures Semperit Group

in EUR million	H1 2016	H1 2015 ¹⁾ restated	Change	Change in EUR million	2015 ¹⁾ restated
Revenue	438.7	450.8	-2.7%	-12.1	914.7
EBITDA	52.8	50.3	+4.8%	+2.4	96.2
EBITDA margin	12.0%	11.2%	+0.8 PP	-	10.5%
EBIT	36.2	36.2	±0.0%	±0.0	66.7
EBIT margin	8.3%	8.0%	+0.3 PP	-	7.3%
Earnings after tax	17.9	25.3	-29.3%	-7.4	46.4
Investments in tangible and intangible assets	25.0	32.3	-22.5%	-7.3	71.8
Employees (at balance sheet date)	7,136	7,311	-2.4%	-175	7,053

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

The negative financial result totalled EUR 10.0 million in the first half of 2016 after EUR 4.2 million in the previous year. The financial result (restated) in the first half of 2015 had been influenced by the positive foreign exchange effects as well as profits from hedging transactions for foreign currencies. Financial income, which now also includes foreign exchange gains (so far included in the item "Other operating income"), decreased to EUR 9.7 million compared to the previous year. Financial expenses, which now also include foreign exchange losses (so far included in the item "Other operating expenses"), increased significantly to EUR 16.6 million compared to the previous year. The reasons for this are primarily the foreign exchange losses (especially in the first quarter of 2016) and the interest expenses due to additional borrowings. In addition, the item "Profit/loss attributable to redeemable non-controlling interests", which is mostly related to companies in the Sempermed and Semperflex segments, increased to EUR 3.1 million in the first half of 2016, following EUR 2.8 million in the previous year.

Income tax expense increased by EUR 1.6 million to EUR 8.3 million. The increase was negatively influenced by the global value adjustment of deferred taxes as well as additional tax payments for prior periods. This also had a negative effect on the tax ratio: it increased from 19.3% to 28.4% (tax rate as a percentage of earnings before tax and redeemable non-controlling interests). Earnings after tax decreased to EUR 17.9 million, resulting in earnings per share of EUR 0.87 in the first half of 2016, following EUR 1.23 in the first half of 2015.

Second quarter of 2016

The Semperit Group recorded a decrease in revenue to EUR 219.2 million or 6.1% in the second quarter of 2016 compared with the second quarter of 2015. The increase in revenue in the Industrial Sector (+1.6%) only partly compensated for the significant decrease in the Medical Sector (-16.3%). In the Industrial Sector, the Semperflex and Semperform segments increased revenues in a quarter-to-quarter comparison, while Sempertrans remained almost exactly on the level of the second quarter of 2015.

EBITDA decreased by 8.6% to EUR 26.1 million and therefore somewhat more than revenue with a decrease of 6.1%. On the one hand, expenses for material and other operating expenses decreased, on the other hand inventories were reduced, which had a negative effect on the operational performance, a significant decrease of the item "Investments in joint ventures and associated companies" and a slight increase of personnel expenses. In addition to the mentioned items, the higher depreciation compared to the quarter of the previous year had an effect on the EBIT that fell by 16.2% to EUR 17.6 million. Earnings after taxes amounted to EUR 7.7 million, while the earnings per share were EUR 0.38.

Key figures Semperit Group / Second quarter

in EUR million	Q2 2016	Q2 2015 ¹⁾ restated	Change	Change in EUR million	2015 ¹⁾ restated
Revenue	219.2	233.4	-6.1%	-14.2	914.7
EBITDA	26.1	28.5	-8.6%	-2.4	96.2
EBITDA margin	11.9%	12.2%	-0.3 PP	-	10.5%
EBIT	17.6	21.0	-16.2%	-3.4	66.7
EBIT margin	8.0%	9.0%	-1.0 PP	-	7.3%
Earnings after tax	7.7	12.7	-39.2%	-5.0	46.4
Investments in tangible and intangible assets	9.0	17.8	-49.8%	-8.9	71.8
Employees (at balance sheet date)	7,136	7,311	-2.4%	-175	7,053

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Dividend

On 26 April 2016, the Annual General Meeting adopted a dividend of EUR 1.20 per share for the year 2015. In total, EUR 24.7 million were distributed. Based on the ordinary dividend, the dividend pay-out ratio for the financial year 2015 was therefore 53.2%, compared with 59.6% in the previous year. Given the share price of EUR 31.10 as at the end of 2015, this results in a dividend yield of 3.9%. Semperit's dividend policy remains unchanged: the pay-out ratio is around 50% of earnings after tax – assuming continued successful performance and that no unusual circumstances occur.

Assets and financial position

Compared with 31 December 2015, the balance sheet total rose by 3.8% to EUR 973.1 million in the first half of 2016. On the asset side of the balance sheet, the main reasons for this increase were expansion investments, an increase in trade receivables and higher cash and cash equivalents, with a decrease in inventories.

On the liabilities side, there were increases in liabilities to banks and currency translation reserves, while trade payables and revenue reserves (due to dividend payment) decreased.

Trade working capital (inventories plus trade receivables minus trade payables) increased from EUR 160.6 million at the end of 2015 to EUR 168.7 million, and therefore constituted 18.7% of the revenue of EUR 902.5 million of the last four quarters (year-end 2015: 17.6%). The increase is attributable to higher trade receivables as well as a decrease in inventories and trade payables.

Cash and cash equivalents increased from EUR 126.4 million at the end of 2015 to EUR 133.0 million as of 30 June 2016.

As of 30 June 2016, the Semperit Group's equity (without non-controlling interests) stood at EUR 356.9 million, EUR 6.3 million lower than at the end of 2015 (EUR 363.3 million). The change resulted from earnings after taxes and the change in the currency translation reserve, as opposed to the dividend payment to the shareholders of the Semperit AG Holding in the second quarter of 2016.

The group's reported equity ratio as of 30 June 2016 amounted to 36.7% (year-end 2015: 38.7%), which is still above the sector average. The capital structure of the Semperit Group therefore remains very solid. The return on equity stood at 10.0%, following 14.0% in the first half of 2015. The return on equity is calculated based on the earnings after tax in relation to the equity of EUR 356.9 million (each both in respect to the portion attributable to the shareholders of Semperit AG Holding).

Debt is slightly higher at EUR 614.2 million compared with the end of 2015. Liabilities from the corporate Schuldschein loans and liabilities to banks total EUR 346.5 million (year-end 2015: EUR 302.6 million). Taking into consideration cash and cash equivalents, this resulted in an overall net debt of EUR 213.5 million (net debt at year-end 2015: EUR 176.1 million). The net debt/EBITDA ratio (net debt in relation to EBITDA of the last four quarters) on 30 June 2016 is therefore 2.16 (year-end 2015: 1.83). The liabilities from redeemable non-controlling interests remained largely unchanged at EUR 46.7 million. Provisions including social capital were almost the same at EUR 71.9 million. Other liabilities and deferred taxes decreased to EUR 53.3 million.

Cash Flow

The gross cash flow in the first half of 2016 amounted to EUR 36.2 million, a year-on-year increase of 10.5%. This change was caused primarily by the change of the items "Earnings before tax", "Depreciation and amortisation" as well as "Share of profits from joint ventures". Cash flow from operating activities improved significantly to EUR 15.6 million in the first half of 2016. Due to the lower investment activities, the cash flow from investing activities decreased to EUR 25.0 million. The cash flow from financing activities rose slightly to EUR 17.1 million.

Related-party transactions with companies and individuals

Please refer to the interim consolidated financial statements for the related-party transactions with companies and individuals.

Investments

At EUR 25.0 million cash-relevant investments in tangible and intangible assets in the first half of 2016 were lower than in the first half of 2015 (EUR 32.3 million). The ratio of capital investment (CAPEX) to depreciation was 1.5 in the first half of 2016 and therefore was below last year's level of 2.3. The investment priorities were on expansion and improvement in the segments Sempermed (expansion of the plant in Kamunting, Malaysia), Semperform (expansion of the site in Wimpassing, Austria and in Germany) and Semperflex (expansion of the hose production at the plant in Odry, Czech Republic).

Employees

As at 30 June 2016, the group's total headcount stood at 7,136 employees, 2.4% below the level at 30 June 2015. The number of employees has decreased in all segments with the exception of Semperflex and the Corporate Center segments. As regards the split of employees by segment, slightly less than half of them are employed in the Sempermed segment, whereas 20% of the employees are engaged in the Semperflex segment and 15% each in the Sempertrans and the Semperform segments.

Performance of the sectors and segments

Industrial Sector

The Industrial Sector (the Semperflex, Sempertrans and Semperform segments) showed a very positive development contrary to the market trend. The Industrial Sector achieved an increase in revenue by 3.7% to EUR 269.0 million despite a challenging economic environment. EBITDA rose by 2.3% to EUR 52.3 million, while EBIT decreased by 1.7% to EUR 42.7 million due to higher depreciation. With more than 50%, the Semperflex segment accounted for the largest share of the Industrial sector, followed by Semperform and Sempertrans at 20% each. The EBITDA and EBIT margins increased in the Semperflex and Sempertrans segments, while they decreased in the Semperform segment. However, the values of the Semperform segment of the first half year 2015 included net earnings from the Leeser acquisition amounting to EUR 3.1 million. Adjusted for these earnings, profitability of Semperform would have increased significantly year-on-year. The sector's EBITDA margin was 19.4% in the first half of 2016 after 19.7% in the previous year, while the EBIT margin was 15.9% after 16.7% in the first half of 2015. Semperflex recorded the highest EBIT margin at 21.5%, followed by Semperform at 12.6% and Sempertrans at 11.7%.

The comparison of the second quarters of 2016 and 2015 showed an increase in revenue as well as a decrease of EBITDA and EBIT – among others due to higher depreciation because of effected investments.

Key figures Industrial Sector

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	269.0	+3.7%	259.3	135.3	+1.6%	133.2	521.0
EBITDA	52.3	+2.3%	51.1	27.2	-6.3%	29.1	93.6
EBITDA margin	19.4%	-0.3 PP	19.7%	20.1%	-1.7 PP	21.8%	18.0%
EBIT	42.7	-1.7%	43.4	22.4	-10.3%	25.0	77.2
EBIT margin	15.9%	-0.8 PP	16.7%	16.6%	-2.2 PP	18.8%	14.8%
Investments in tangible and intangible assets	10.3	-37.1%	16.3	3.0	-59.1%	7.4	35.1
Employees (at balance sheet date)	3,570	±0.0%	3,571	3,570	±0.0%	3,571	3,576

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Semperflex segment

The Semperflex segment generated further high profitability and slightly declining revenue thanks to excellent production and sales performances in a declining market. The business unit for hydraulic hoses achieved sales successes primarily in Europe, while North America and Asia recorded weaker demand. In total, sales of hydraulic hoses increased.

The test run for the new capacities for industrial hoses in Odry, Czech Republic, started and sales developed positively. All capacities were well utilised due to strategic partnerships with key customers.

Sempertrans segment

The Sempertrans segment defended its position in established markets and expanded its market position in new regions and market segments. This was achieved against the background of a stabilisation of raw material prices for mining products, which continue to be on a low level. However, overall demand for investment goods in the mining industry remained subdued and the price pressure accordingly high. This also applies to conveyor belts. Considering the challenging market and competitive environment the utilisation of production capacities was satisfying. However, year-on-year, sales could be increased, in particular for steel cord reinforced conveyor belts.

However, visibility of demand became significantly shorter and was characterised by rising uncertainty and strong price pressure. Thus it was necessary to react flexibly to market requirements. In total, revenue increased and profitability was satisfying.

Semperform segment

In a difficult market environment with declining demand, the Semperform segment profited from gaining market shares in the handrail business and from the successful integration of the German profile manufacturer Leeser (inclusion in the consolidated financial statements as of 1 May 2015 as a fully consolidated subsidiary). The first of two new extrusion lines by Leeser was put into operation in the second quarter of 2016. Sales of the window and door profiles were increased compared with the first half of 2015 despite the difficult market environment in Russia and Ukraine, which caused further declines of the business volume in these markets. Demand for products of the business unit Semperit Engineered Solutions increased slightly, though it continued to show a volatile development. The business unit Special Applications increased sales.

In the summary of all business units, revenue increased. The development of operating profitability is satisfactory – taking into account that the values of the first half year of 2015 include a positive special effect of approximately EUR 3.1 million from the Leeser acquisition. Profitability was also improved by measures to enhance efficiency and minimise costs.

Key figures Semperflex

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	106.3	-1.5%	107.9	53.6	+2.0%	52.5	203.4
EBITDA	27.2	+1.2%	26.9	13.9	+4.9%	13.3	46.1
EBITDA margin	25.6%	+0.7 PP	24.9%	26.0%	+0.7 PP	25.3%	22.7%
EBIT	22.9	+0.1%	22.9	11.8	+4.6%	11.3	38.2
EBIT margin	21.5%	+0.3 PP	21.2%	22.0%	+0.5 PP	21.5%	18.8%
Investments in tangible and intangible assets	4.1	-48.6%	7.9	1.7	-52.3%	3.5	14.6
Employees (at balance sheet date)	1,566	2.9%	1,522	1,566	+2.9%	1,522	1,536

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Key figures Sempertrans

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	81.6	+4.7%	77.9	38.9	-0.2%	39.0	164.9
EBITDA	11.4	+9.8%	10.4	5.7	-0.7%	5.7	23.2
EBITDA margin	14.0%	+0.6 PP	13.4%	14.5%	-0.1 PP	14.6%	14.0%
EBIT	9.5	+8.1%	8.8	4.7	-3.4%	4.9	19.9
EBIT margin	11.7%	+0.4 PP	11.3%	12.1%	-0.4 PP	12.5%	12.1%
Investments in tangible and intangible assets	1.5	-71.3%	5.3	0.7	-73.3%	2.5	12.3
Employees (at balance sheet date)	1,056	-1.9%	1,076	1,056	-1.9%	1,076	1,086

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Key figures Semperform

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	81.1	+10.2%	73.5	42.8	+2.7%	41.7	152.8
EBITDA	13.6	-1.2%	13.8	7.7	-24.0%	10.1	24.3
EBITDA margin	16.8%	-2.0 PP	18.8%	17.9%	-6.3 PP	24.2%	15.9%
EBIT	10.2	-12.5%	11.7	5.9	-33.0%	8.8	19.1
EBIT margin	12.6%	-3.3 PP	15.9%	13.8%	-7.4 PP	21.2%	12.5%
Investments in tangible and intangible assets	4.7	+51.2%	3.1	0.7	-51.5%	1.5	8.1
Employees (at balance sheet date)	948	-2.6%	973	948	-2.6%	973	954

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Medical Sector: Sempermed segment

The development of the Sempermed segment was characterised by a difficult market environment. This included increased production costs due to higher gas and electricity rates in Malaysia, which could not entirely be passed on to the market, as well as a challenging pricing policy of individual competitors, in particular for nitrile gloves. Raw material prices included a rise in the second quarter of 2016, in particular for natural latex. This increase could only be passed on to the market with a certain delay. In addition, the increased use of merchandise enhanced the margin situation. The negative impact of the cooperation with the joint venture partner in Thailand persisted and had an negative impact on the operational business.

The previous expansion of the production capacities at the Malaysian site were satisfying. In order to improve profitability a cost reduction program has been started at the end of the second quarter of 2016.

Revenue of the Sector fell by 11.4% to EUR 169.7 million due to heavy price pressure and a weak start of the year 2016. EBITDA decreased to EUR 7.9 million, while EBIT fell to EUR 1.2 million. The EBIT margin was 0.7%. Comparison of the second quarters of 2016 and 2015 showed a decrease of revenue, EBITDA and EBIT.

Demand for examination gloves improved during the course of the first half of 2016. Especially the structured market access to the Industrial (occupational health and retail) and Medical market segments contributed to this development. From a regional point of view, Europe and Latin America developed well, while sales in the USA showed a weaker performance. Sales of surgical gloves, which are produced in the core production facility in Wimpassing, Austria, showed development above average due to higher demand in the core markets compared to the previous year.

For further information on the arbitration proceedings against the joint venture partner Sri Trang-Agro Industry Public Co Ltd. Group or the joint venture company Siam Sempermed Corp. Ltd. (SSC) please refer to page 35f.

Key figures Sempermed

in EUR million	H1 2016	Change	H1 2015 ¹⁾ restated	Q2 2016	Change	Q2 2015 ¹⁾ restated	2015 ¹⁾ restated
Revenue	169.7	-11.4%	191.5	83.8	-16.3%	100.1	393.7
EBITDA	7.9	-31.7%	11.6	1.8	-72.9%	6.8	29.4
EBITDA margin	4.7%	-1.3 PP	6.0%	2.2%	-4.6 PP	6.8%	7.5%
EBIT	1.2	-78.1%	5.5	-1.7	-	3.6	17.2
EBIT margin	0.7%	-2.2 PP	2.9%	-2.0%	-5.5 PP	3.5%	4.4%
Investments in tangible and intangible assets	11.3	-10.0%	12.6	4.5	-44.0%	8.1	29.6
Employees (at balance sheet date)	3,337	-8.1%	3,630	3,337	-8.1%	3,630	3,344

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Outlook

In July 2016, the International Monetary Fund (IMF) adjusted its estimates slightly downwards for the current year and forecast a global economic growth of 3.1% (2015: 3.1%) in 2016. In the industrialised countries the moderate economic recovery against the background of low raw material prices should continue with the GDP rising by 1.8% (2015: 1.9%). The USA is likely to see a 2.2% rise and the euro area 1.6%, albeit affected by the decision of Great Britain to leave the EU ("BREXIT"). However, the emerging and developing countries show a heterogeneous picture: While countries which were in economic troubles in 2015 – these include several countries in Latin America and the Middle East – show signs of moderate recovery, the IMF expects a further slowdown in growth to 6.6% in China. All in all, the IMF assumes a growth of 4.1% (2015: 4.0%) for 2016 in the emerging and developing countries.

In 2016, Semperit expects no significant changes of the market conditions compared to 2015. The generally low demand in the Industrial Sector is expected to continue due to the economic situation. In particular in Eastern Europe and Russia, no economic upturn is to be expected. Especially in China the investment situation in the industry does not show any sign of recovery. In the economically insensitive Medical Sector, increased raw material and energy prices and continuing price pressure are to be expected, while demand will develop steadily and market growth is between 5% and 6%. From the current perspective, the Semperit Group is not capable of achieving the operational results of 2015 due to the unsatisfactory income contribution of the Sempermed segment.

Outlook Industrial Sector

In the next months of 2016, Semperit refers to a good order situation even though a slowdown is possible in some business segments. The production capacities of Semperflex are well booked although high growth rates similar to the past years cannot be expected in the current financial year 2016 due to market and capacity conditions. At Sempertrans the booking situation of the production capacities is satisfying despite the difficult situation in the customer markets. However, demand is characterised by a rising uncertainty and strong price pressure. The business development of the Semperform segment is assessed as stable for the next months. All in all, Semperit nevertheless expects a business trend for the Industrial Sector that is better than the development of the total market.

Outlook Medical Sector

In the Medical Sector (Sempermed segment) the focus will be on the implementation of further production capacities in Malaysia. The profitability shall be improved by continuing process optimisations and efficiency enhancements as well as realising a cost reduction programme. The financial burdens due to the Thai joint venture will probably persist.

Continuation of the growth strategy and long-term targets

The Semperit Group will continue its growth strategy consistently despite difficult economic conditions. The focus will be on the entering into new markets in the Industrial Sector and the expansion and optimisation of existing production capacities. In the Medical Sector, the focus will be set on the expansion of the glove production in Malaysia in addition to further production and sales optimisations as well as efficiency enhancements. Altogether, capital investments (CAPEX) of approximately EUR 60 million are planned for 2016.

Going forward, Semperit aims at achieving average double-digit volume growth (quantities sold) and attractive earnings margins. The aspired range of a target margin is between 11% and 14% for EBITDA and between 8% and 11% for EBIT.

Note


This outlook is based on the assessments of the Management Board as of 17 August 2016, and does not take into account the effects of possible acquisitions, divestments or other unforeseeable structural or economic changes during the further course of 2016. These assessments are subject to both known and unknown risks and uncertainties, which may result in actual events and outcomes differing from the statements made here.

Events after the balance sheet date

No events subject to disclosure occurred between the balance sheet date on 30 June 2016 and the date of authorisation for issue of this report on 17 August 2016.

Vienna, 17 August 2016

The Management Board



Thomas Fahnemann
Chief Executive Officer



Johannes Schmidt-Schultes
Chief Financial Officer



Declan Daly
Chief Information Officer



Richard Ehrenfeldner
Chief Operating Officer
Sempermed



Michele Melchiorre
Chief Technical Officer

Interim consolidated financial statements and notes

Consolidated income statement

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾	1.4.- 30.6.2016	1.4.- 30.6.2015 restated ¹⁾
Revenue	438,678	450,825	219,159	233,370
Changes in inventories	-3,759	2,955	-2,891	891
Own work capitalised	2,210	3,086	887	2,107
Operating revenue	437,129	456,866	217,156	236,367
Other operating income	5,670	7,048	4,002	4,871
Cost of material and purchased services	-247,037	-273,327	-123,186	-139,462
Personnel expenses	-87,893	-83,575	-44,504	-42,797
Other operating expenses	-57,935	-63,577	-28,045	-34,112
Share of profits from joint ventures and associated companies	2,825	6,901	639	3,635
Earnings before interest, tax, depreciation and amortisation (EBITDA)	52,761	50,336	26,062	28,502
Depreciation, amortisation and impairment of tangible and intangible assets	-16,534	-14,093	-8,447	-7,484
Earnings before interest and tax (EBIT)	36,227	36,243	17,615	21,017
Financial income	9,699	12,872	939	4,659
Financial expenses	-16,594	-14,280	-3,476	-7,957
Profit/loss attributable to redeemable non-controlling interests	-3,100	-2,786	-1,577	-1,856
Financial result	-9,995	-4,195	-4,115	-5,154
Earnings before tax	26,232	32,048	13,500	15,863
Income taxes	-8,342	-6,730	-5,757	-3,119
Earnings after tax	17,890	25,317	7,743	12,744
thereof attributable to the shareholders of Semperit AG Holding	17,902	25,330	7,755	12,752
thereof attributable to non-controlling interests	-12	-13	-12	-8
Earnings per share in EUR (diluted and undiluted)²⁾	0.87	1.23	0.38	0.62

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

²⁾ Attributable to the shareholders of Semperit AG Holding.

Consolidated statement of comprehensive income

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾	1.4.- 30.6.2016	1.4.- 30.6.2015 restated ¹⁾
Earnings after tax according to the consolidated income statement	17,890	25,317	7,743	12,744
Other comprehensive income				
Amounts that will not be recognised through profit and loss in future periods²⁾				
Remeasurements of defined benefit plans (IAS 19)	-4,281	0	-4,281	0
Related deferred taxes	467	0	467	0
	-3,814	0	-3,814	0
Amounts that will potentially be recognised through profit and loss in future periods				
Available-for-sale financial assets				
Revaluation gains / losses for the period	296	-206	111	-416
Cash flow hedges				
Revaluation gains / losses for the period	-1,338	577	-1,340	743
Reclassification to profit and loss for the period	0	824	0	798
	-1,338	1,401	-1,340	1,541
Other comprehensive income from joint ventures				
Currency translation differences for the period	1,072	6,704	2,289	-6,811
Currency translation differences				
Currency translation differences for the period	4,106	9,793	-2,448	-13,537
Related deferred taxes	239	-297	288	-281
	4,375	17,394	-1,100	-19,505
Other comprehensive income	561	17,394	-4,914	-19,505
Total recognised comprehensive income	18,451	42,711	2,829	-6,760
thereof on earnings attributable to the shareholders of Semperit AG Holding	18,349	42,707	2,852	-6,770
thereof on earnings attributable to non-controlling interests	102	4	-23	9

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

²⁾ Reevaluation due to material development of interest rate parameters during the year.

Consolidated cash flow statement

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾
Earnings before tax	26,232	32,048
Depreciation, amortisation, impairment and write-ups of tangible and intangible assets	16,534	14,093
Profit and loss from disposal of assets (including current and non-current financial assets)	6	-27
Change in non-current provisions	-880	-816
Share of profits from joint ventures and associated companies	-2,825	-6,901
Badwill arising from company acquisition	0	-3,403
Profit/loss attributable to redeemable non-controlling interests	3,100	2,786
Net interest income (including income from securities)	2,465	1,576
Interest paid	-1,177	-900
Interest received	489	498
Taxes paid on income	-7,767	-6,213
Gross cash flow	36,177	32,740
Change in inventories	5,476	-12,151
Change in trade receivables	-8,728	-29,940
Change in other receivables and assets	505	-10,954
Change in trade payables	-13,726	20,365
Change in other liabilities and current provisions	-3,594	5,089
Changes in working capital resulting from currency translation adjustments	-485	4,736
Cash flow from operating activities	15,625	9,886
Proceeds from sale of tangible and intangible assets	69	206
Investments in tangible and intangible assets	-25,022	-32,286
Net cash outflow on acquisition of businesses (less cash acquired)	0	-17,474
Cash flow from investing activities	-24,954	-49,554
Cash receipts from current and non-current financing liabilities	41,927	150,219
Repayment of current and non-current financing liabilities	-85	-7,942
Dividend to shareholders of Semperit AG Holding	-24,688	-123,441
Acquisition of non-controlling interests	-28	-34
Cash flow from financing activities	17,126	18,802
Net increase / decrease in cash and cash equivalents	7,797	-20,866
Effects resulting from currency translation	-1,263	3,172
Cash and cash equivalents at the beginning of the period	126,430	115,574
Cash and cash equivalents at the end of the period	132,964	97,879

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Consolidated balance sheet

in EUR thousand	30.6.2016	31.12.2015 restated ¹⁾
ASSETS		
Non-current assets		
Intangible assets	116,169	111,314
Tangible assets	294,777	276,630
Investments in joint ventures and associated companies	106,567	102,670
Other financial assets	10,926	12,372
Other assets	8,557	5,275
Deferred taxes	14,593	16,717
	551,589	524,978
Current assets		
Inventories	130,235	135,711
Trade receivables	134,247	125,519
Other financial assets	4,682	2,284
Other assets	12,183	16,670
Current tax receivables	7,232	6,192
Cash and cash equivalents	132,964	126,430
	421,543	412,806
ASSETS	973,132	937,784
EQUITY AND LIABILITIES		
Equity		
Share capital	21,359	21,359
Capital reserves	21,503	21,503
Revenue reserves	306,332	317,733
Currency translation reserve	7,728	2,664
Equity attributable to the shareholders of Semperit AG Holding	356,922	363,260
Non-controlling interests	1,997	1,924
	358,919	365,183
Non-current provisions and liabilities		
Provisions for pension and severance payments	44,329	40,775
Other provisions	11,268	11,421
Liabilities from redeemable non-controlling interests	46,706	44,192
Corporate Schuldschein loan	132,644	132,615
Liabilities to banks	204,607	162,898
Other financial liabilities	1,263	862
Other liabilities	814	746
Deferred taxes	11,411	11,924
	453,042	405,433
Current provisions and liabilities		
Provisions for pension and severance payments	2,865	2,866
Other provisions	13,412	19,033
Corporate Schuldschein loan	3,187	1,481
Liabilities to banks	6,063	5,560
Trade payables	95,787	100,660
Other financial liabilities	17,804	13,762
Other liabilities	17,843	19,037
Current tax liabilities	4,210	4,769
	161,171	167,168
EQUITY AND LIABILITIES	973,132	937,784

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Consolidated statement of the changes in equity

in EUR thousand	Revenue reserves						Currency translation reserve	Total equity attributable to the shareholders of Semperit AG Holding	Non-controlling interests	Total equity
	Share capital	Capital reserves	Re-valuation reserves	Other revenue reserves	Total revenue reserves					
As at 1.1.2015	21,359	21,503	284	393,405	393,690	7,211	443,762	2,211	445,973	
Earnings after tax	0	0	0	25,330	25,330	0	25,330	-13	25,317	
Other comprehensive income	0	0	-155	1,052	898	16,480	17,377	17	17,394	
Total recognised comprehensive income	0	0	-155	26,382	26,228	16,480	42,707	4	42,711	
Dividend	0	0	0	-123,441	-123,441	0	-123,441	0	-123,441	
Acquisition of non-controlling interests	0	0	0	3	3	0	3	-37	-34	
As at 30.6.2015 restated¹⁾	21,359	21,503	130	296,349	296,479	23,690	363,031	2,178	365,209	
As at 1.1.2016 restated¹⁾	21,359	21,503	200	317,533	317,733	2,664	363,260	1,924	365,183	
Earnings after tax	0	0	0	17,902	17,902	0	17,902	-12	17,890	
Other comprehensive income	0	0	222	-4,840	-4,617	5,064	447	114	561	
Total recognised comprehensive income	0	0	222	13,063	13,285	5,064	18,349	102	18,451	
Dividend	0	0	0	-24,688	-24,688	0	-24,688	0	-24,688	
Acquisition of non-controlling interests	0	0	0	2	2	0	2	-29	-28	
As at 30.6.2016	21,359	21,503	423	305,909	306,332	7,728	356,922	1,997	358,919	

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Notes to the interim consolidated financial statements

Preparation and presentation of the interim consolidated financial statements

These interim consolidated financial statements have been prepared in accordance with the Prime Market rules of the Vienna Stock Exchange and with International Financial Reporting Standards (IFRS) as well as IAS 34 for interim financial statements.

For more information on accounting and valuation methods, please see the consolidated financial statements as of 31 December 2015, which in this regard form the basis for these interim financial statements.

Material changes to the accounting and valuation methods relate to the recognition of the foreign exchange gains or losses in the consolidated income statement. For more details please see the next section in this report.

The reporting currency is the Euro, in which case figures are rounded off to thousands of Euros, unless specified otherwise. Rounding differences in the totalling of rounded amounts and percentages may arise from the automatic processing of data.

These interim consolidated financial statements of the Semperit Group have not been audited or reviewed by the group's auditor.

Retrospective restatements regarding the recognition of foreign exchange gains and losses – Foreign Exchange Restatement

As an internationally operating group, Semperit is subject to various foreign exchange effects within the scope of its business activities. For the purpose of a more effective internal management as well as a more transparent presentation in the external financial reports of Semperit Group and its segments, foreign exchange gains or losses in the consolidated income statement are no longer shown as part of the operating result in other operating income / other operating expenses anymore since 1 January 2016, but in financial income / financial expenses and therefore the financial result. In order to ensure comparability with the quarters of the previous year and the previous year following the change of method pursuant to IAS 8, all comparable figures for 2015 are presented according to the same new accounting method in this report.

Effect on the consolidated income statement as of 30 June 2015

The restated consolidated income statement as of 30 June 2015 is as follows:

in EUR thousand	1.1.- 30.6.2015	Restatement	1.1.- 30.6.2015 restated
Revenue	450,825	0	450,825
Changes in inventories	2,955	0	2,955
Own work capitalised	3,086	0	3,086
Operating revenue	456,866	0	456,866
Other operating income	19,439	-12,391	7,048
Cost of material and purchased services	-273,327	0	-273,327
Personnel expenses	-83,575	0	-83,575
Other operating expenses	-73,152	9,575	-63,577
Share of profits from joint ventures and associated companies	6,901	0	6,901
Earnings before interest, tax, depreciation and amortisation (EBITDA)	53,152	-2,817	50,336
Depreciation, amortisation and impairment of tangible and intangible assets	-14,093	0	-14,093
Earnings before interest and tax (EBIT)	39,059	-2,817	36,243
Financial income	481	12,391	12,872
Financial expenses	-4,706	-9,575	-14,280
Profit/loss attributable to redeemable non-controlling interests	-2,786	0	-2,786
Financial result	-7,012	2,817	-4,195
Earnings before tax	32,048	0	32,048
Income taxes	-6,730	0	-6,730
Earnings after tax	25,317	0	25,317
thereof attributable to the shareholders of Semperit AG Holding	25,330	0	25,330
thereof attributable to non-controlling interests	-13	0	-13
Earnings per share in EUR (diluted and undiluted)¹⁾	1.23	0.00	1.23

¹⁾ Attributable to the shareholders of Semperit AG Holding.

Effect on the consolidated income statement as of 31 December 2015

The restated consolidated income statement as of 31 December 2015 is as follows:

in EUR thousand	1.1.- 31.12.2015	Restatement	1.1.- 31.12.2015 restated
Revenue	914,686	0	914,686
Changes in inventories	6,788	0	6,788
Own work capitalised	6,217	0	6,217
Operating revenue	927,691	0	927,691
Other operating income	37,099	-27,953	9,145
Cost of material and purchased services	-555,785	0	-555,785
Personnel expenses	-164,813	0	-164,813
Other operating expenses	-160,639	23,548	-137,092
Share of profits from joint ventures and associated companies	17,078	0	17,078
Earnings before interest, tax, depreciation and amortisation (EBITDA)	100,630	-4,406	96,224
Depreciation, amortisation and impairment of tangible and intangible assets	-29,478	0	-29,478
Earnings before interest and tax (EBIT)	71,152	-4,406	66,746
Financial income	1,252	27,953	29,206
Financial expenses	-8,228	-23,548	-31,776
Profit/loss attributable to redeemable non-controlling interests	-5,395	0	-5,395
Financial result	-12,371	4,406	-7,965
Earnings before tax	58,781	0	58,781
Income taxes	-12,419	0	-12,419
Earnings after tax	46,363	0	46,363
thereof attributable to the shareholders of Semperit AG Holding	46,394	0	46,394
thereof attributable to non-controlling interests	-31	0	-31
Earnings per share in EUR (diluted and undiluted)¹⁾	2.26	0.00	2.26

¹⁾ Attributable to the shareholders of Semperit AG Holding.

Principles and methods of consolidation

The consolidated financial statements include the financial statements of the parent company and the financial statements of the companies under its control, i.e. the subsidiaries of the parent. The group controls a company when it is exposed, or has rights, to variable returns from its involvement with the company and has the ability to affect those returns through its power over the company. The financial statements of subsidiaries are included in the consolidated financial statements from the time at which control begins until the time at which control ends.

On the assessment whether the definition of control within the meaning of IFRS 10 is met where the group's de facto shareholding in subsidiaries is either 50% or 41.43%, please refer to the consolidated financial statements as of 31 December 2015, note 3.1., page 96ff. In the first half of 2016 there have been no material developments that would have led to a revised assessment of control within the meaning of IFRS 10.

Adoption of revised accounting standards

The following amended standards were applicable for the first time in the reporting period from 1 January until 30 June 2016:

First-time adoption of standards		Effective date ¹⁾	Endorsement
Amended standards			
IFRS 11	Joint Arrangements — Amendments: Accounting for Acquisitions of Interests in Joint Operations	1.1.2016	November 2015
IAS 1	Presentation of Financial Statements — Amendments: Disclosure Initiative	1.1.2016	December 2015
IAS 19	Employee Benefits — Amendments: Employee Contributions	1.2.2015	December 2014
IAS 27	Separate Financial Statements — Amendments: Equity Method in Separate Financial Statements	1.1.2016	December 2015
IAS 16, 38	Property, Plant and Equipment and Intangible Assets — Amendments: Clarification of Acceptable Methods of Depreciation and Amortisation	1.1.2016	December 2015
IAS 16, 41	Property, Plant and Equipment and Agriculture — Amendments: Bearer Plants	1.1.2016	November 2015
Misc.	Annual Improvements to IFRS, cycle 2010–2012	1.2.2015	December 2014
Misc.	Annual Improvements to IFRS, cycle 2012–2014	1.1.2016	December 2015

¹⁾ According to the Official Journal of the EU, the standards are obligatory for financial years commencing on or after the effective date.

The listed amended standards are not of relevance for the Semperit Group or do not have a material effect on the interim or annual consolidated financial statements.

Changes in the scope of consolidation

There were no changes in the scope of consolidation during the first half of 2016.

Equity transactions

In the first half of 2016 an additional 0.02% interest in Latexx Partners Berhad was acquired for EUR 28 thousand.

As of 30 June 2016 the group's interest totalled 98.52%, up from 98.50% as of 31 December 2015. In the first half of 2015 a 0.02% interest was acquired for EUR 34 thousand, increasing the group's total interest to 98.48% as of 30 June 2015.

The transactions in the first half of 2016 and in the first half of 2015 were accounted for as equity transactions. For further information, please refer to the explanations on the principles and methods of consolidation in the consolidated financial statements as of 31 December 2015.

Investments in joint ventures and associated companies (equity method)

The investments in joint ventures and associated companies are comprised as follows:

in EUR thousand	30.6.2016	31.12.2015 restated ¹⁾
Joint ventures		
Siam Sempermed Corp. Ltd., Hat Yai, Thailand	104,223	100,535
Associated companies		
Synergy Health Allershausen GmbH, Allershausen, Germany	2,344	2,135
	106,567	102,670

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

The change in the investments in joint ventures and associated companies is as follows:

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾	1.1.- 31.12.2015 restated ¹⁾
As at 1.1.	102,670	82,835	82,835
Proportionate period result and intercompany elimination results	2,825	6,901	17,078
Currency translation	1,072	6,704	2,545
Revaluation of defined benefit obligation	0	0	211
As at 30.6. / 31.12.	106,567	96,440	102,670

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

As of 31 December 2014 the method of consolidation of SSC was changed from full consolidation under IFRS 10 Consolidated Financial Statements to the equity method in accordance with IFRS 11 Joint Arrangements and IAS 28 Investments in Associates and Joint Ventures.

As the result of a special audit of the consolidated financial statements as at 31 December 2013 and the consolidated interim financial statements as at 30 June 2014, the Austrian Financial Market Authority (FMA) reached the conclusion in its decision from 30 July 2015 that SSC was no longer eligible for full consolidation already as at 30 June 2014.

Based on this finding of error as of 30 June 2015, the above-mentioned change in the method of consolidation used for SSC as at 31 December 2014 (from full consolidation to the equity method) was retrospectively restated to 31 March 2014.

At the end of August 2015 Semperit AG Holding submitted an appeal to the Austrian Federal Administrative Court against the decision mentioned above. Following the FMA's negative preliminary decision on the appeal, Semperit AG Holding submitted in November 2015 a corresponding application for appeal to the Austrian Federal Administrative Court for a ruling.

The appeal to the Austrian Federal Administrative Court was withdrawn by Semperit AG Holding in July 2016.

Investments in joint ventures

The consolidated carrying amount of the investment in Siam Sempermed Corp. Ltd. totalled EUR 104,223 thousand as of 30 June 2016 (31 December 2015: EUR 100,535 thousand). As of 30 June 2016 group companies conducted transactions that resulted in the following assets and liabilities against the joint venture, and their business relationships resulted in the following income and expenses in 2016 and 2015:

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾
Revenue	1,239	947
Other operating income	245	244
Cost of material and purchased services	77,714	69,307
	30.6.2016	31.12.2015 restated¹⁾
Inventories	17,105	16,167
Trade receivables	1,682	1,319
Trade payables	19,089	24,533

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Investments in associated companies

The consolidated carrying amount of the investment in Synergy Health Allershausen GmbH totalled EUR 2,344 thousand as of 30 June 2016 (31 December 2015: EUR 2,135 thousand). As of 30 June 2016 group companies conducted transactions that resulted in the following assets and liabilities against the associated company, and their business relationships resulted in the following income and expenses in 2016 and 2015:

in EUR thousand	1.1.- 30.6.2016	1.1.- 30.6.2015 restated ¹⁾
Other operating expenses	188	185
Financial income	3	3
	30.6.2016	31.12.2015 restated¹⁾
Other financial assets	566	566
Trade payables	31	173

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Segment Reporting

in EUR thousand	Sempermed	Semperflex	Sempertrans	Semperform	Corporate Center and Group eliminations	Group
1.1.-30.6.2016						
Revenue	169,726	106,320	81,566	81,067	0	438,678
EBITDA	7,900	27,212	11,448	13,637	-7,435	52,761
EBIT = segment result	1,202	22,908	9,541	10,220	-7,644	36,227
1.1.-30.6.2015 restated¹⁾						
Revenue	191,526	107,895	77,872	73,532	0	450,825
EBITDA	11,571	26,881	10,425	13,806	-12,348	50,336
EBIT = segment result	5,477	22,891	8,826	11,686	-12,638	36,243

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

The income and expenses of companies involved in production and distribution in more than one segment are subdivided and allocated to the appropriate segments accordingly so that no further eliminations are necessary. The Corporate Center consists of Semperit AG Holding, which is not involved in operating activities, and those portions of a management company in China and a service company in Singapore that are allocated to the Corporate Center. Internal charging and the allocation of Corporate Center costs have already been made to the segments as far as possible.

In the first half of 2016 the result of the segment Semperflex is affected by an impairment of EUR 12 thousand due to the impairment of land. In the first half of 2015 there were no impairments on either tangible or intangible assets.

Investments in and disposals of tangible and intangible assets

In the first half of 2016 the Semperit Group made investments in tangible and intangible assets totalling EUR 25,022 thousand (previous year: EUR 32,286 thousand). In contrast, tangible and intangible assets with a net carrying amount of EUR 76 thousand (previous year: EUR 179 thousand) were sold.

Obligations to acquire tangible assets

As of 30 June 2016 the group has contractual obligations to acquire tangible assets totalling EUR 24,572 thousand (31 December 2015: EUR 30,835 thousand). The decrease compared to the previous year is due to the completion and commissioning of investment projects to expand production capacity.

Indicator-based Impairment Test Sempermed

The reported goodwill is allocated to the cash-generating units (CGU) of Semperit as of 30 June 2016 as disclosed in the table below. The Sempermed related goodwill as of 30 June 2016 increased due to its foreign currency translation on the closing date.

Cash generating unit in EUR thousand	30.6.2016	31.12.2015 restated ¹⁾
Segment Sempermed	87,444	82,963
Segment Semperflex	1,693	1,693
Segment Sempertrans	71	71
	89,208	84,727

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

As a result of the current business and earnings development of the Sempermed segment in the second quarter of 2016, being amongst other issues attributable to tight market conditions and increasing cost levels, as well as with the intention to validate the mid- and long-term growth and earnings prospects of this segment, Semperit performed an indicator-based impairment test of the Sempermed segment as of 30 June 2016.

Regarding its underlying commercial planning data, this impairment test as of 30 June 2016 reflects the updated mid- and long-term expectations of the segment management as well as current capital market parameters. Concerning the applied valuation methods and techniques, there are no material changes in comparison to the last annual impairment tests of Semperit group as of 31 December 2015.

As of 30 June 2016, the recoverable amount of the Sempermed segment is based on its value in use, which is calculated using discounted future cash flows. These forecasted cash flows were determined using the budget for the 2016 financial year that was approved by the Management Board and the Supervisory Board. In addition, an updated mid-term business plan based on organic growth (i.e. growth from own business activities without consideration of acquisitions) covering the next five years was taken into account. The budget and the business plan are based on assumptions made by segment management on the development of their markets, the market share of their segments and specific business initiatives. Key planning parameters are sales volumes and EBIT margins, which are determined within the mid-term planning process in close alignment with strategic product and customer/sales initiatives.

These assumptions are subject to forecasting uncertainties. All corporate planning data include certain assumptions and measures to expand the segment's capacity and to improve its infrastructure. Any forecasted cash flows from such assumptions or measures were not considered for this impairment test if the implementation of these measures had not yet started as at the reporting date. Any changes in working capital are derived from internally defined targets for the respective segment.

A terminal growth rate of 0.75% (previous year: 1.5%) is used for the timeframe beyond the detailed planning horizon within the CGU Sempermed. This terminal growth rate is based on expected long-term market growth rates being refined by expected levels of inflation as of the valuation date.

The discount rate used is the weighted average cost of capital (WACC) as derived by the use of the capital asset pricing model. When determining this WACC discount rate, a Medical Sector (equivalent to the Sempermed segment) specific peer group is taken into consideration, being identical with the peer group used as at 31 December 2015. The pre-tax discount rate, which was individually determined for the Sempermed segment, was 8.1% (previous year: 9.4%).

This indicator-based impairment test confirmed the recoverability of the recognised goodwill of the Sempermed segment as of 30 June 2016. As the carrying amount of the Sempermed CGU was lower than its recoverable amount (value in use), no goodwill impairment loss had to be recognised.

The value in use is largely determined by its terminal value (present value of a perpetual annuity), which is especially sensitive to changes in assumptions regarding free cash flows, long-term growth rates and the WACC discount rate. Management regards the following negative changes in parameters as possible.

Change in parameters	2016 Sempermed	2015 Sempermed
Discount rate (WACC)	+ 1 percentage point	+ 1 percentage point
Long-term growth rate	-1 percentage point	-1 percentage point
Change in free cash flows	-10% change	-10% change

In the sensitivity analyses performed, each individual parameter was changed in isolation, without consideration of a simultaneous change in other parameters.

In addition, an expanded sensitivity analysis was performed in which the parameters were changed in isolation so that the estimated recoverable amount as of 30 June 2016 would be equivalent to the carrying amount. The results of this analysis are shown in the following table.

Change in parameters	2016 Sempermed
Discount rate (WACC)	+1.89 percentage points
Long-term growth rate	-2.62 percentage points
Change in free cash flows	-27.95 percentage points

With the exception of goodwill, the Semperit Group and the Sempermed segment have no other intangible assets with an indefinite useful life.

Disclosures on financial instruments

The following tables show the carrying amounts of the individual financial assets and liabilities classified in accordance with the valuation categories stipulated in IAS 39.9.

Assets

in EUR thousand	Valuation category IAS 39	Carrying Amount 30.6.2016	Carrying amount 31.12.2015 restated ¹⁾
Trade receivables	Loans and receivables	134,247	125,519
Other financial assets			
Securities	Available-for-sale	6,783	6,490
Loans to associated companies	Loans and receivables	563	563
Other loans	Loans and receivables	12	11
Derivative financial instruments	Held for trading	2,699	4,469
Derivative financial instruments	Designated as a hedging instrument	64	0
Other financial assets	Loans and receivables	5,488	3,123
Cash and cash equivalents			
Cash on hand, cheques and cash deposits in banks	–	132,964	126,430

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Liabilities

in EUR thousand	Valuation category IAS 39	Carrying Amount 30.6.2016	Carrying amount 31.12.2015 restated ¹⁾
Corporate Schuldschein loan	Liabilities at amortised cost	135,831	134,096
Liabilities from redeemable non-controlling interests	Liabilities at amortised cost	46,706	44,192
Trade payables	Liabilities at amortised cost	95,787	100,660
Liabilities to banks	Liabilities at amortised cost	210,670	168,458
Other financial liabilities			
Derivative financial liabilities	Held for trading	1	240
Derivative financial liabilities	Designated as a hedging instrument	1,380	0
Liabilities from finance leases	Liabilities at amortised cost	60	91
Other financial liabilities	Liabilities at amortised cost	17,625	14,293

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

Fair value

The three levels in the fair value hierarchy are defined as follows:

- Level 1: measurement based on quoted prices on an active market for a specific financial instrument.
- Level 2: measurement based on quoted market prices for similar instruments or on the basis of valuation models based exclusively on input factors that are observable on the market.
- Level 3: measurement based on models with significant input factors that are not observable on the market.

In the first half of 2016 there were no reclassifications of financial instruments between the above mentioned levels.

Assets and liabilities at fair value

Financial instruments at fair value include securities and derivative financial instruments.

in EUR thousand	Valuation category IAS 39	Fair Value 30.6.2016	Fair Value 31.12.2015 restated ¹⁾	Level
Assets				
Securities	Available-for-sale	6,783	6,490	1
Derivative financial instruments	Held for trading	2,699	4,469	2
Derivative financial instruments	Designated as a hedging instrument	64	0	2
Liabilities				
Derivative financial liabilities	Held for trading	1	240	2
Derivative financial liabilities	Designated as a hedging instrument	1,380	0	2

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

The fair values of available-for-sale securities are determined using publicly available prices.

The derivative financial instruments held for trading purposes are foreign exchange forward contracts.

The derivative financial instruments designated as hedges are cross currency swaps as well as further foreign exchange forward contracts. Their fair values of the cross currency swaps are determined using generally accepted financial valuation models, in which future cash flows are simulated using the yield curves published on the closing date. In addition, the carrying amount is adjusted to take into account the credit risk of the respective counterparty. When doing so, positive exposures are measured considering the default risk of the counterparty, while negative exposures are measured considering the group's own default risk.

The fair values of the foreign exchange forward contracts are determined using generally accepted financial valuation models (e.g. determination of the present value of expected future cash flows based on current foreign exchange rates and yield curves).

Assets and liabilities not measured at fair value

The fair value of all other financial assets and liabilities, except for the following items and liabilities from redeemable non-controlling interests, corresponds to their carrying amount.

in EUR thousand	Valuation category IAS 39	Fair Value 30.6.2016	Fair Value 31.12.2015 restated ¹⁾	Level
Liabilities				
Corporate Schuldschein loan	Liabilities at amortised cost	153,326	144,794	3
Liabilities from finance leases	Liabilities at amortised cost	61	92	3

¹⁾ Values restated, see page 19f. in this report (Foreign Exchange restatement).

The fair value of the corporate Schuldschein loan was determined by discounting the contractual payment streams with current interest rates. The comparable interest rates as at the reporting date were derived from capital market yields with matching maturities and then adjusted for current risk and liquidity costs that are observable on the market. These comparable interest rates were derived based on management's current assessment of the rating of the Semperit Group.

For existing fixed-interest finance lease liabilities, current third-party interest rates were queried and then compared with the contractually agreed interest rates. As a result, the difference between the carrying amount and the fair value shows the margin between the contractually agreed historical return and the return currently available on the market. The finance lease liabilities are shown under the item other financial liabilities.

For information on the valuation of liabilities from redeemable non-controlling interests, please refer to the explanations in the consolidated financial statements as of 31 December 2015. The calculation of the fair value would require a disproportionately high effort and is thus not disclosed in this report.

Debt capital structure of the Semperit Group

Since 2015 the Semperit Group uses increasingly financial debt instruments for its financing purposes. On the one hand, these financial debt instruments include a term loan of EUR 100 million and a revolving credit line up to EUR 150 million out of a syndicated loan facility / Rahmenkreditvertrag (SLF/RKV 2014).

On the other hand, Semperit Group has issued two corporate Schuldschein loans (SSD 2013 and SSD 2015) with a nominal value of EUR 58 million and EUR 75 million respectively.

Corporate Schuldschein loan and interest rate swaps

In July 2013 Semperit AG Holding issued a corporate Schuldschein loan totalling EUR 125 million (SSD 2013). In the second quarter of 2014 and in the first quarter of 2015, additional corporate Schuldschein loans amounting to EUR 5 million with the same conditions as the 10-year fixed-interest tranche of the original corporate Schuldschein loan were issued to "Privatstiftung zur Förderung der Gesundheit von Beschäftigten der Semperit AG Holding" (in English: Private Foundation to Promote the Health of the Employees of Semperit AG Holding). Consequently, the total notional volume increased to EUR 130 million. The average interest rate of this Schuldschein offering was 2.35%.

In June 2015 Semperit AG Holding redeemed the variable five- and seven-year tranches (notional volume EUR 36,500 thousand and EUR 35,500 thousand) of the existing corporate Schuldschein loan from 2013. At almost the same time in July 2015, Semperit AG Holding issued a new corporate Schuldschein loan for a total amount of EUR 75,000 thousand (SSD 2015) in order to take advantage of the decline in financing costs. This corporate Schuldschein loan consists of three long-term fixed-interest tranches with durations of seven, ten and fifteen years. The average interest rate of this second Schuldschein offering was 2.16%. This Schuldschein loan was primarily placed in Austria and Germany. The cash inflows in July 2015 were primarily used to repay the variable tranches of the previous corporate Schuldschein loan from July 2013.

As of 30 June 2016 accrued interest amounting to EUR 3,187 thousand is recognized with the current liabilities section. The differences between the carrying amounts excluding interest (clean prices) and the nominal amounts are the transaction cost of the Schuldschein offerings in July 2013 and July 2015. These differences are allocated over the terms of the corporate Schuldschein tranches in accordance with the effective interest rate method.

In October 2013, Semperit entered into two interest rate swaps (hedged notional volume of EUR 30,240 thousand) to hedge the variable-interest-rate tranches of the corporate Schuldschein loan from 2013. Both interest rate swaps were accounted for as cash flow hedges in accordance with IAS 39. When the variable tranches of the corporate Schuldschein loan were redeemed in July 2015, both interest rate swaps were settled as well and the hedge accounting relationships were terminated.

Cross Currency Swaps and foreign exchange forward contracts

In order to hedge Semperit's financing to a subsidiary company issued in Malaysian Ringgit, Semperit AG Holding entered into a Cross Currency Swap in April 2015. On the one hand, the Cross Currency Swap causes the variable refinancing to be converted into fixed interest rates, on the other hand, the exchange rate of the Euro and the Malaysian ringgit is fixed. According to IAS 39 the Cross Currency Swap is classified as a cash flow hedge (regarding interest rate risk) and as a fair value hedge (regarding the foreign exchange risk) too. In total, the derivative was accounted for at fair value. As of 31 December 2015 the requirements for hedge accounting in accordance with IAS 39 were no longer met. Since then, all changes in valuation are recognized completely through profit and loss within the financial result section of the consolidated income statement.

In order to hedge Semperit's further financing to a subsidiary company issued in Malaysian ringgit, Semperit AG Holding entered into an additional Cross Currency Swap in March 2016. On the one hand, the Cross Currency Swap again causes the variable refinancing to be converted into fixed interest rates, on the other hand, the exchange rate of the Euro and the Malaysian ringgit is fixed. According to IAS 39 this Cross Currency Swap is also classified as a cash flow hedge (regarding interest rate risk) and as a fair value hedge (regarding the foreign exchange risk). In total, this derivative is also accounted for at fair value. During the first half year 2016 the effective portion of this cash flow hedge of EUR -2 thousand was recognized in other comprehensive income. As of 30 June 2016 the cash flow hedge reserve from the second Cross Currency Swap amounts to EUR -2 thousand (31 December 2015: EUR 0 thousand).

Furthermore, there are cash flow hedges in connection with foreign exchange forward contracts in US Dollar and Polish Zloty. In the first half of 2016, fair value changes of these cash flow hedges were recognised in other comprehensive income with the amount of EUR -1,336 thousand. As of 30 June 2016 the cash flow hedge reserve from foreign exchange forward contracts is EUR -1,336 thousand (31 December 2015: EUR 0 thousand).

All in all, the cash flow hedge reserve amounts to EUR -1,338 thousand as of 30 June 2016 (31 December 2015: EUR 0 thousand).

Defined benefit plans

In the case of defined benefit plans of the Semperit Group, the cost of providing the benefit is calculated using the Projected Unit Credit Method; for this purpose, an actuarial assessment is carried out at each balance sheet date. Remeasurements of provisions for pensions and severance payments due to actuarial gains and losses are reported directly in equity within the other comprehensive income section in accordance with IAS 19 (2011). On the contrary, actuarial remeasurements of provisions for other long-term benefits such as long-services bonuses are recognised through profit and loss as personnel expenses in accordance with IAS 19 (2011).

As of 30 June 2016, an actuarial assessment was carried out for provisions for pensions, severance payments and long-service bonuses, due to the further declining interest rate levels. This resulted in an increase of the provisions for pensions and severance payments by EUR 4,281 thousand recognised in the other comprehensive income section as well as in an increase of the provision for long-service bonuses of EUR 318 thousand reported in the consolidated income statement.

Dividend and treasury shares

On 26 April 2016 the Annual General Meeting adopted a dividend of EUR 1,20 per share, for the year 2015. A total of EUR 24,688 thousand was distributed on 6 May 2016 (previous year: EUR 123,441 thousand).

Semperit AG Holding has no treasury stock as of 30 June 2016.

Contingent liabilities

There were no material changes in contingent liabilities since the last reporting date as of 31 December 2015.

Related-party transactions with companies and individuals

Outstanding balances and transactions between Semperit AG Holding and its subsidiaries were eliminated in the course of consolidation and are not further discussed here.

B & C Semperit Holding GmbH is the direct majority shareholder of Semperit AG Holding, and

B & C Privatstiftung is the dominant legal entity. B & C Holding Österreich GmbH is the shareholder holding an indirect majority stake which draws up and publishes consolidated financial statements in which the Semperit Group is consolidated. Under IAS 24, B & C Privatstiftung and all its subsidiaries, joint ventures and associated companies are related parties of the Semperit Group.

Related parties of the Semperit Group include the members of the Management and Supervisory Boards of Semperit AG Holding, the managing directors and supervisory board members of all companies which directly or indirectly hold a majority stake in Semperit AG Holding, and finally the members of the management board of B & C Privatstiftung and the close family members of these management and supervisory board members and managing directors.

With the other related parties mentioned below the group has the following transactions:

In first half of 2016 the group conducted transactions with unit-it GmbH in the amount of EUR 225 thousand (previous year: EUR 474 thousand). This related to the purchase and maintenance of SAP licences and was conducted at arm's length conditions. As of 30 June 2016 there are no unpaid liabilities to the company (previous year: EUR 0 thousand).

In first half of 2016 the group conducted transactions with Grohs Hofer Rechtsanwälte Gesellschaft m.b.H. and Grohs Hofer Rechtsanwälte GmbH & Co KG in the amount of EUR 186 thousand (previous year: EUR 132 thousand). These transactions relate to legal consulting services and were conducted at arm's length conditions. As of the reporting date there are unpaid liabilities of EUR 41 thousand to these companies (previous year: EUR 19 thousand).

The remaining level of transactions with associated companies and other related parties is low, and they are conducted on normal business terms and conditions.

Transactions with co-partners

The fully consolidated company Semperflex Asia Corp. Ltd. has a business relationship with the non-controlling co-partner of this subsidiary, Sri Trang Agro-Industry Public Co Ltd.

In addition, Sempertrans Best (Shandong) Belting Co. Ltd. conducts business with Wang Chao Coal & Electricity Group, the non-controlling co-partner of this subsidiary.

Supervisory Board matters

The Annual General Meeting on 26 April 2016 elected Stephan B. Tanda into the Supervisory Board, Andreas Schmidradner has been re-elected. Ingrid Wesseln has left the Supervisory Board on her own request.

In the subsequent Supervisory Board meeting Dr. Veit Sorger has been re-elected as Chairman of the Supervisory Board and Dr. Felix Strohbichler as his deputy. Totalling, the Supervisory Board continues to consist of 12 members.

Management Board matters

In the meeting as at 26 April 2016 the Supervisory Board of the Semperit AG Holding extended the mandate of the Chairman Thomas Fahnemann for an additional period of office till 31 December 2019.

In the same meeting the Supervisory Board appointed Michele Melchiorre for three years as a member of the Management Board. His mandate commenced on 1 June 2016. Mr. Melchiorre will be responsible as technical director for the Industrial Sector. Richard Ehrenfeldner is focused on the development of the Sempermed segment.

Legal disputes involving the Siam Sempermed Corp. Ltd. joint venture

Since 2014, the Semperit Group has been involved in several legal proceedings with domestic courts in Thailand and with international arbitration tribunals seated in Zurich based on the rules of the International Chamber of Commerce (ICC). These proceedings relate in particular to the competencies and internal organisation of the Board of Directors (BoD) being the management body of Siam Sempermed Corp. Ltd. (SSC), a joint venture in Thailand. They also concern the business conduct of SSC, SSC's business relationships with group subsidiaries of the Thai joint venture partner, Sri Trang Agro-Industry Public Co Ltd. (Sri Trang), and the exclusive distribution rights of the Semperit Group.

The opposing parties in the arbitration proceedings are the contracting parties in the joint venture agreements and SSC itself. In the proceedings at Thai courts, the opposing parties are the BoD members who have been nominated by Sri Trang. Semperit is the plaintiff in the ICC proceedings. The BoD members appointed by Semperit are the defendants in most of the proceedings at Thai courts.

The core issue at dispute is that the members of SSC's BoD who have been nominated by the joint venture partner Sri Trang are currently hindering the exercise of control by Semperit.

Due to this inability to exercise control over SSC and the assessment of a loss of control under IFRS 10.B24, Semperit decided to change the method of consolidation for SSC as of 31 March 2014, from full consolidation according to IFRS 10 to the equity method in accordance with IFRS 11 / IAS 28 (see note 2.18. in the annual report 2015).

ICC Cases

Currently, the arbitration proceedings are mostly at an advanced or final stage; the arbitration tribunals have been constituted and case management conferences have been held. Semperit has then prepared and submitted detailed statements of claim and additional briefs. In addition, hearings were held where witnesses were questioned.

ICC 1 Case

In the second quarter 2016, a final award was rendered in favour of Semperit in the arbitration proceeding against the joint venture partners concerning the possibility to pass board resolutions with a reduced quorum. The arbitral tribunal decided that the Sri Trang nominated directors of SSC cannot and may not block SSC's decision-making and also the Casting Vote of the Semperit nominated Chairman, by not participating in board meetings. Further, the joint venture partners are ordered to bear the costs of the arbitration proceedings and of the ICC Court and to reimburse to Semperit an amount of approximately EUR 2.5 million (net value less the costs of arbitration already paid to the ICC). The joint venture partners defaulted in payment within the period stipulated. As a consequence Semperit took necessary legal actions to execute this claim. Semperit recognised the claim in accordance with IAS 37.11 as of 30 June 2016.

Semperit will, for the time being, not change the current method of consolidation (according to the equity method) in relation to SSC.

ICC 2 Case

In the first quarter 2016, a partial award was rendered in the arbitration proceedings against the joint venture partner concerning the business operations and the business relationships with the joint venture company SSC. The arbitral tribunal decided that Sri Trang and the other Thai joint venture partners must comply with Semperit's request for access to SSC's accounts and company records as well as for the restoration of transparency at SSC. Other contentious issues that have not been included in the partial award remain subject of the ongoing proceedings.

ICC 3 Case

In the second quarter of 2016, a Partial Award in this case was issued. The arbitration tribunal decided, that SSC itself has to fulfill the demands of Semperit of restoration for transparency, access to the books and accounts and access to the premises.

For all ICC Cases, the 30-day-periods for application to set aside the (partial) awards have expired according to Swiss Law.

Thailand Cases

Several proceedings are still pending at the Thai courts. Some of these lawsuits were submitted by a Sri Trang nominated director against SSC directors nominated by Semperit and against SSC itself.

Semperit nominated directors have also initiated a lawsuit against Sri Trang nominated directors. In this litigation, the court of appeal overturned the lower court decision and confirmed the legal position of the Semperit directors. The counterparty is entitled to file an appeal against this decision.

Additionally, Semperit has sued two Sri Trang nominated SSC directors.

At the beginning of 2016, one of the Sri Trang nominated directors commenced a lawsuit against the validity of one shareholders' resolution regarding a shareholder-audit, which was previously passed by an unanimous consent of all SSC shareholders.

In these proceedings, further court hearings are expected until the end of 2016.

BWB Case

In October 2015, the Austrian Federal Competition Authority (BWB) – acting on a petition from Sri Trang companies, which are Semperit's joint venture partners in SSC – commenced a proceeding against Semperit and these Sri Trang companies with the antitrust court in Vienna. The proceeding relates to exclusive distribution rights in Europe. In December 2015, Semperit submitted extensive briefs to defend its legal position. In the first quarter 2016, a court hearing was held and Semperit submitted additional briefs. By the end of June 2016, the antitrust court in Vienna determined in a partial ruling the incompatibility of the exclusive distribution rights with the legal regulations of the EU Competition Law. In July 2016, Semperit filed an appeal with the Austrian Supreme Court. Semperit also proposed that this legal issue be decided by the European Court of Justice because there has so far been no ruling in similar cases on the prohibition of distribution regulations.


The Semperit Group continues to anticipate that its interpretation of the law will be confirmed in these proceedings. The costs for the proceedings in which Semperit is the claimant are being expensed as incurred. Appropriate provisions have been set up for the expected costs of the proceedings in which Semperit is the defendant.

Events after the balance sheet date

No significant events requiring disclosure occurred between 30 June 2016, the balance sheet date, and 17 August 2016, the date on which this report was approved for publication.

Vienna, 17 August 2016

The Management Board




Thomas Fahnemann
Chief Executive Officer



Johannes Schmidt-Schultes
Chief Financial Officer



Declan Daly
Chief Information Officer



Richard Ehrenfeldner
Chief Operating Officer
Sempermed



Michele Melchiorre
Chief Technical Officer


Statement of all legal representatives

Pursuant to Section 87 (1) line 3 of the Austrian Stock Exchange Act

We confirm to the best of our knowledge that the condensed interim consolidated financial statements as at 30 June 2016 prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU) give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and that the group management report gives a true and fair view of important events that have occurred during the first six months of the financial year and their impact on the condensed interim financial statements, of the principal risks and uncertainties for the remaining six months of the financial year and of the major related party transactions to be disclosed.

Vienna, 17 August 2016

The Management Board




Thomas Fahnemann
Chief Executive Officer



Johannes Schmidt-Schultes
Chief Financial Officer



Declan Daly
Chief Information Officer



Richard Ehrenfeldner
Chief Operating Officer
Sempermed



Michele Melchiorre
Chief Technical Officer

Contact

Semperit AG Holding

Modecenterstrasse 22
1031 Vienna, Austria
Tel.: +43 1 79 777 0
Fax: +43 1 79 777 600
www.semperitgroup.com/en

Investor Relations

Stefan Marin
Tel.: +43 1 79 777 210
investor@semperitgroup.com
www.semperitgroup.com/en/ir

Addresses of the Semperit Group

www.semperitgroup.com/en/contact

Financial Calendar 2016

18.8.2016	Half-year financial report 2016
17.11.2016	Report on the first three quarters 2016

Financial Calendar 2017

23.3.2017	Publication of 2016 annual financial statements and press conference
16.4.2017	Record date of the Annual General Meeting
26.4.2017	Annual General Meeting
28.4.2017	Last possible day to purchase shares entitled to receive the dividend
2.5.2017	Dividend ex day
3.5.2017	Dividend record date (= day at the end of which CSD Austria determines the securities entitled to receive the dividend)
4.5.2017	Dividend payment day
16.5.2017	Report on the first quarter of 2017
17.8.2017	Half-year financial report 2017
16.11.2017	Report on the first three quarters 2017

Contacts of the Semperit Group

Ownership and publisher: Semperit Aktiengesellschaft Holding, Modecenterstrasse 22, 1031 Vienna, Austria
Produced in-house with FIRE.sys.

Disclaimer

The terms "Semperit" or "Semperit Group" in this report refer to the group; "Semperit AG Holding" or "Semperit Aktiengesellschaft Holding" is used to refer to the parent company (individual company).

This interim report of the Semperit Group has not been audited or reviewed by the group's auditor.

We have prepared this report and verified the information it contains with the greatest possible care. In spite of this, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the totalling of rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this report are based on the knowledge and information available and the assessments made at the time that this report was prepared (editorial deadline: 17 August 2016). As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements.

All references to people are gender neutral.

This report has been produced in German and English. In case of doubt, the German version shall take precedence.

